BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 5728339)

  • 41. [Colpocytohistological correlations of lesions of the uterine portio extending to the fornix vaginae].
    Volante E; Devalle G; Lerro R
    Minerva Ginecol; 1981 Apr; 33(4):337-40. PubMed ID: 7243076
    [No Abstract]   [Full Text] [Related]  

  • 42. Dysplasia of the cervix.
    Kistner RW
    Int Surg; 1972 Feb; 57(2):124-5. PubMed ID: 5024759
    [No Abstract]   [Full Text] [Related]  

  • 43. [Premalignant dysplasias due to ovulation inhibitors?].
    Mestwerdt G
    Munch Med Wochenschr; 1972 Apr; 114(16):771-3. PubMed ID: 5067886
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C; Austin RM
    Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What will you say about HPV?
    Vaughn D
    Tenn Med; 2005 Aug; 98(8):397-9. PubMed ID: 16315467
    [No Abstract]   [Full Text] [Related]  

  • 46. [Electron microscopy of the cervix, In dysplasias, in situ and invasive carcinomas].
    Jiménez Cardoso JM; Sanginés A; Leuze QE; Sanguinés A
    Ginecol Obstet Mex; 1972 Jul; 32(189):53-8. PubMed ID: 5057416
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of cervical smears at King Hussein Medical Centre, Jordan, over three and a half years.
    Malkawi SR; Abu Hazeem RM; Hajjat BM; Hajjiri FK
    East Mediterr Health J; 2004; 10(4-5):676-9. PubMed ID: 16335662
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Possibilities of cytological diagnosis of precancerous and inflammatory diseases of the uterine cervix].
    Daian-Barsegian OA
    Zh Eksp Klin Med; 1968; 8(2):41-9. PubMed ID: 5759433
    [No Abstract]   [Full Text] [Related]  

  • 49. Pertinence of an in vitro murine system to early identification of developing human cervical carcinoma.
    Koprowska I
    Acta Cytol; 1970 May; 14(5):270-5. PubMed ID: 5284265
    [No Abstract]   [Full Text] [Related]  

  • 50. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
    Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytologic, vascular, and histologic patterns of dysplasia, carcinoma in situ and early invasive carcinoma of the cervix.
    Johannisson E; Kolstad P; Söderberg G
    Acta Radiol Diagn (Stockh); 1966; ():Suppl 258:1+. PubMed ID: 5964746
    [No Abstract]   [Full Text] [Related]  

  • 52. The natural history of Pap test screening in a rural population.
    Rosenfeld JA
    Tenn Med; 1998 May; 91(5):179-82. PubMed ID: 9584605
    [No Abstract]   [Full Text] [Related]  

  • 53. Cervicography--an adjunct to Papanicolaou screening.
    Ferris DG
    Am Fam Physician; 1994 Aug; 50(2):363-70. PubMed ID: 8042572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytological and follow-up study of the irradiation response of patients with cervical carcinoma.
    An SH
    Laval Med; 1968 Jan; 39(1):1-7. PubMed ID: 5639482
    [No Abstract]   [Full Text] [Related]  

  • 55. Dysplasia, carcinoma in situ, and invasive carcinoma of the cervix uteri in previously screened women.
    Hoeg K; Roger V
    Scand J Clin Lab Invest Suppl; 1968; 106():173-80. PubMed ID: 5731703
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical aspects of corpus carcinoma].
    Husslein H; Stöger H
    Fortschr Med; 1974 Feb; 92(5):171-4. PubMed ID: 4820296
    [No Abstract]   [Full Text] [Related]  

  • 57. Epidemiologic evidence for the spectrum of change from dysplasia through carcinoma in situ to invasive cancer.
    Johnson LD; Nickerson RJ; Easterday CL; Stuart RS; Hertig AT
    Cancer; 1968 Nov; 22(5):901-14. PubMed ID: 5686639
    [No Abstract]   [Full Text] [Related]  

  • 58. A statistical model of the natural history of cervical neoplastic disease: the duration of carcinoma in situ.
    Barron BA; Cahill MC; Richart RM
    Gynecol Oncol; 1978 Apr; 6(2):196-205. PubMed ID: 648944
    [No Abstract]   [Full Text] [Related]  

  • 59. PAP class III A: a 'proliferating' problem in cervical cytology.
    Vooijs GP; van der Graaf Y; de Schipper F
    Eur J Obstet Gynecol Reprod Biol; 1988 Nov; 29(3):219-26. PubMed ID: 3220172
    [No Abstract]   [Full Text] [Related]  

  • 60. The intrauterine device and cervical neoplasia. A prospective study of patients with cervical dysplasia.
    Richart RM; Barron BA
    JAMA; 1967 Mar; 199(11):817-9. PubMed ID: 6071295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.